We are live on ! Find out more

Harmony Biosciences

HRMY

Market cap $2.42B

41.52 USD

+0.42

1.02%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

41.52

0.00

0%

1 day

1.02%

5 days

0.05%

1 month

5.06%

3 months

17.95%

6 months

44.22%

Year to date

11.08%

1 year

24.24%

5 years

14.89%

10 years

12.19%

About: Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Employees: 293

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 79.4%

Neutral 20.6%

Negative 0%

Zacks Investment Research

Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock?

Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece.

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

Zacks Investment Research

4 Healthcare Stocks to Watch as Defensive Demand Strengthens

Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.

4 Healthcare Stocks to Watch as Defensive Demand Strengthens

Zacks Investment Research

4 Stocks Trading Near 52-Week High With More Upside Potential

Stocks like SNX, AMP, HRMY and NWL are seeing price strength and have a high chance of carrying the momentum forward.

4 Stocks Trading Near 52-Week High With More Upside Potential

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated

Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold.

Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated

Zacks Investment Research

HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up

HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.

HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up

Zacks Investment Research

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

See News Rankings

Price charts implemented using Lightweight Charts™